Radioactive Isotopes for Nuclear Therapy
Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes diagnostic and therapeutic radioactive isotopes and advanced PET and SPECT radiotracers.
Its flagship product, the radioisotope Lutetium-177 (both C.A and N.C.A), has attracted considerable attention and exhibited great promise in treating a variety of late-stage cancers, including metastatic prostate cancer and neuroendocrine tumors.
Its production facilities include an advanced nuclear pharmacy that provides radionuclide labelled compounds for PET/SPECT imaging, a cyclotron facility, and an aseptic manufacturing plant that also offers contract manufacturing services (CMO).
| Name | Isotopia Molecular Imaging |
|---|---|
| Slug | isotopia |
| Type / kind | startup |
| Crunchbase ID | isotopia-molecular-imaging |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP-bt88IDA |
| Status | active |
|---|---|
| Last update | 2026-05-17 |
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Petah Tikva |
| HQ address | Alexander Yanai Street 39, Petah Tikva, Israel |
| Total raised | $3.8M |
|---|---|
| Current stage | Mature |
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}